318 related articles for article (PubMed ID: 28408179)
1. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency.
Mueller C; Gernoux G; Gruntman AM; Borel F; Reeves EP; Calcedo R; Rouhani FN; Yachnis A; Humphries M; Campbell-Thompson M; Messina L; Chulay JD; Trapnell B; Wilson JM; McElvaney NG; Flotte TR
Mol Ther; 2017 Jun; 25(6):1387-1394. PubMed ID: 28408179
[TBL] [Abstract][Full Text] [Related]
2. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
[TBL] [Abstract][Full Text] [Related]
3. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
[TBL] [Abstract][Full Text] [Related]
5. Current status of gene therapy for α-1 antitrypsin deficiency.
Loring HS; Flotte TR
Expert Opin Biol Ther; 2015 Mar; 15(3):329-36. PubMed ID: 25363251
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
[TBL] [Abstract][Full Text] [Related]
7. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin.
Sosulski ML; Stiles KM; Frenk EZ; Hart FM; Matsumura Y; De BP; Kaminsky SM; Crystal RG
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759494
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector.
Lu Y; Choi YK; Campbell-Thompson M; Li C; Tang Q; Crawford JM; Flotte TR; Song S
J Gene Med; 2006 Jun; 8(6):730-5. PubMed ID: 16518879
[TBL] [Abstract][Full Text] [Related]
10. Gene Delivery of Alpha-1-Antitrypsin Using Recombinant Adeno-Associated Virus (rAAV).
Song S; Lu Y
Methods Mol Biol; 2018; 1826():183-196. PubMed ID: 30194601
[TBL] [Abstract][Full Text] [Related]
11. Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency.
Chiuchiolo MJ; Kaminsky SM; Sondhi D; Hackett NR; Rosenberg JB; Frenk EZ; Hwang Y; Van de Graaf BG; Hutt JA; Wang G; Benson J; Crystal RG
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):161-73. PubMed ID: 24191907
[TBL] [Abstract][Full Text] [Related]
12. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR
Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464
[TBL] [Abstract][Full Text] [Related]
13. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.
Calcedo R; Somanathan S; Qin Q; Betts MR; Rech AJ; Vonderheide RH; Mueller C; Flotte TR; Wilson JM
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1655-1659. PubMed ID: 28137880
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.
Flotte TR; Brantly ML; Spencer LT; Byrne BJ; Spencer CT; Baker DJ; Humphries M
Hum Gene Ther; 2004 Jan; 15(1):93-128. PubMed ID: 14965381
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency.
Chiuchiolo MJ; Kaminsky SM; Sondhi D; Mancenido D; Hollmann C; Crystal RG
Hum Gene Ther Clin Dev; 2014 Sep; 25(3):112-33. PubMed ID: 25238276
[No Abstract] [Full Text] [Related]
16. Gene-based therapy for alpha-1 antitrypsin deficiency.
Mueller C; Flotte TR
COPD; 2013 Mar; 10 Suppl 1():44-9. PubMed ID: 23527792
[TBL] [Abstract][Full Text] [Related]
17. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.
Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR
Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566
[TBL] [Abstract][Full Text] [Related]
18. Safety of Intravenous Administration of an AAV8 Vector Coding for an Oxidation-Resistant Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency.
Rosenberg JB; De BP; Greco A; Gorman N; Kooner V; Chen A; Yost-Bido M; Munoz-Zuluaga C; Kaminsky SM; Rostami M; Monette S; Crystal RG; Sondhi D
Hum Gene Ther; 2023 Feb; 34(3-4):139-149. PubMed ID: 36606685
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin.
De B; Heguy A; Leopold PL; Wasif N; Korst RJ; Hackett NR; Crystal RG
Mol Ther; 2004 Dec; 10(6):1003-10. PubMed ID: 15564132
[TBL] [Abstract][Full Text] [Related]
20. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
